Non-parametric inference of adverse events under informative censoring

Statistics in Medicine

Volumn 25, Issue 23, 2006, Pages 3981-4003

  Nishikawa, Masako ^a   Tango, Toshiro ^a   Ogawa, Makiko ^b  

^a NATIONAL INSTITUTE OF PUBLIC HEALTH   (Japan)

^b Sanofi Aventis KK ^*  (Japan)

Author keywords

Cumulative incidence function; Cumulative joint incidence; Recurrent event with competing risks; Terminating event; Time to event data

Indexed keywords

ANTINEOPLASTIC AGENT;

ARTICLE; CANCER CHEMOTHERAPY; CLINICAL ARTICLE; COMPETENCE; DISEASE SEVERITY; DRUG SURVEILLANCE PROGRAM; HUMAN; INCIDENCE; INFERENTIAL STATISTICS; LOG RANK TEST; NONPARAMETRIC TEST; PROBABILITY; RECURRENCE RISK; RISK ASSESSMENT; SAMPLE SIZE; TREATMENT DURATION; TREATMENT FAILURE; UNSPECIFIED SIDE EFFECT;

ANTINEOPLASTIC AGENTS; CLINICAL TRIALS; COMPUTER SIMULATION; DATA INTERPRETATION, STATISTICAL; HUMANS; NEOPLASMS; PATIENT DROPOUTS; RISK ASSESSMENT;

EID: 37849186091     PISSN: 02776715     EISSN: 10970258     Source Type: Journal    
DOI: 10.1002/sim.2511     Document Type: Article

References (22)

1. Johnson JR, Williams G, Pazdur R. End points and United States Food and Drug Administration approval of oncology drugs. Journal of Clinical Oncology 2003; 21:1404-1411.
2. ICH Steering Committee. ICH harmonized tripartite guideline Statistical principles for clinical trials. Statistics in Medicine 1999; 18:1905-1942.
3. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. Journal of the American Statistical Association 1958; 53:457-481.
4. Gooley TA, Leisenring W, Crowley J, Storer BE. Estimation of failure probabilities in the presence of Competing risks: new representation of old estimators. Statistics in Medicine 1999; 18:695-706.
5. Pepe MS, Mori M. Kaplan-Meier, marginal, or conditional probability curves in summarizing competing risks failure time data? Statistics in Medicine 1993; 12:737-751.
6. Cox DR, Oakes D. Analysis of Survival Data. Chapman & Hall/CRC: London, 1984.
7. Choudhury JB. Non-parametric confidence interval estimation for competing risks analysis: application to contraceptive data. Statistics in Medicine 2002; 21:1129-1144.
8. Wang W, Wells MT. Nonparametric estimation of successive duration times under dependent censoring. Biometrika 1998; 85:561-572.
9. Pepe MS. Inference for events with dependent risks in multiple endpoint studies. Journal of the American Statistical Association 1991; 86:770-778.
10. Kalbfleisch JD, Prentice RL. The Statistical Analysis of Failure Time Data. Wiley: New York, 1980.
11. Dinse GE, Larson MG. A note on semi-Markov models for partially censored data. Biometrika 1986; 73: 379-386.
12. Greenwood M. A report on the natural duration of cancer. Reports on Public Health and Medical Subjects 1926; 33:1-26.
13. Lin DY, Sun W, Ying Z. Non-parametric estimation of the gap time distributions for serial events with censored data. Biometrika 1999; 86:59-70.
14. Efron B. Censored data and bootstrap. Journal of the American Statistical Association 1981; 76:312-321.
15. Nishikawa M, Tango T. Counter-intuitive properties of the Kaplan-Meier estimator. Statistics and Probability Letters 2003; 65:353-361.
16. Kalbfleisch JD, Prentice RL. The Statistical Analysis of Failure Time Data (2nd edn). Wiley: New Jersey, 2002.
17. Cook RJ, Lawless JF. Marginal analysis of recurrent events and a terminating event. Statistics in Medicine 1997; 16:911-924.
18. Ghosh D, Lin DY. Nonparametric analysis of recurrent events and death. Biometrics 2000; 56:554-562.
19. Li QH, Lagakos SW. Use of the Wei-Lin-Weissfeld method for the analysis of a recurring and a terminating event. Statistics in Medicine 1997; 16:925-940.
20. Wei L, Lin DY, Weissfeld L. Regression analysis of multivariate failure time data. Biometrika 1989; 68: 373-379.
21. Gray RJ. A class of k-sample tests for comparing the cumulative incidence of a competing risk. Annals of Statistics 1988; 16:1141-1154.
22. Lin DY. Non-parametric inference for cumulative incidence functions in competing risks studies. Statistics in Medicine 1997; 16:901-910.